Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7085007 | 0.86 | MAPT (0.59) | SMN1; SMN2KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL7543801 | 0.85 | PARP1 (0.55) | TNKS2SMN1; SMN2KDM4ELMNAALDH1A1 | |
| SCHEMBL28499182 | 0.83 | ALDH1A1 (0.51) | TNKS2SMN1; SMN2KDM4ELMNACRHBP | |
| SCHEMBL30176871 | 0.77 | TNKS2 (0.57) | TNKS2SMN1; SMN2KDM4EALDH1A1PARP1 | |
| SCHEMBL25364009 | 0.76 | TNKS2 (0.56) | TNKS2SMN1; SMN2KDM4ELMNAPARP1 | |
| SCHEMBL6793345 | 0.76 | MDM2 (0.59) | TNKS2KDM4EALDH1A1PARP1PARP2 | |
| Hydrochloric Acid SCHEMBL6795779 | 0.75 | TNKS2 (0.55) | TNKS2KDM4ELMNAPARP1MAPT | |
| SCHEMBL4743261 | 0.75 | HSD17B10 (0.69) | TNKS2SMN1; SMN2KDM4ELMNAALDH1A1 | |
| SCHEMBL7560891 | 0.75 | CYP2C19 (0.44) | SMN1; SMN2KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL5523733 | 0.74 | L3MBTL1 (0.59) | KDM4ELMNAALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380205-B1 | QUINAZOLINE THROUGH A C1-C4ALKYL, C1- C4ALKENYL, C1-C4ALKYNYL, C1-C4ALKOXY, AMINO, AMINOC1-C4ALKYL, HYDROXYC1-C4ALKYL, CARBONYL, CYCLOC3-C6ALKYL OR AMINOCARBONYL CHAIN, USEFUL FOR TREATMENT OF THE PAIN | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | MERCK & CO., INC. | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032207-A1 | 2-Cyclohexyl quinazoline NMDA/NR2B antagonists | GRIN2C, GRIN1, GRIN3A | TNKS2 2389/4885SMN1; SMN2 1522/4885KDM4E 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.